Compare Mesoblast Limited (MESO) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Tidewater Inc — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Tidewater Inc trades at $76.1 (market cap $3.75B). The key difference: Tidewater Inc is the larger of the two by market cap, and Tidewater Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | TDW | |
|---|---|---|
Market Cap | $2.17B | $3.75B |
Sector | Technology | Utilities |
52-Week High | $20.96 | $91.12 |
52-Week Low | $12.88 | $47.29 |
Enterprise Value | $2.17B | $3.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Tidewater (TDW) trades at $75.43, down 0.51% today, with a bullish technical outlook supported by moving averages but recent earnings misses in Q1 and Q4 2026. The company maintains strong profitability with a 22.16% net margin and a P/E of 12.79, while news highlights an acquisition by FTAI Infrastructure (GlobeNewsWire, June 29, 2026).
Outlook is mixed: valuation appears reasonable with solid cash flow, but earnings volatility and sector headwinds pose risks. Analyst consensus leans hold (61.54%), suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
